Biogen, PDL say daclizumab trial meets main goal
Pharma Times (subscription) - London,UK
... say that an ongoing Phase II trial of their humanised monoclonal antibody daclizumab has met its primary endpoint in relapsing multiple sclerosis. ...
See all stories on this topic

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients ...
PipelineReview.com (press release) - Barcelona,Spain
... placebo-controlled trial of daclizumab, met its primary endpoint in relapsing multiple sclerosis (MS) patients being treated with interferon beta. ...
See all stories on this topic